Evaluation of Indoxyl Sulfate in Chronic Kidney Disease associated with Left Ventricular Hypertrophy

Abstract

Chronic kidney disease CKD is widely prevalent globally and Left ventricular hypertrophy (LVH) is very common among CKD patients and contributes to CV mortality which can be monitored by measuring the levels of indoxyl sulfate (IS). Study the correlation of indoxyl sulphate and the degree of left Ventricular hypertrophy in CKD patients. A case control study was done on 90 patients with Chronic kidney disease CKD, 45 of them with who were recruited the Imamian Al-Khadhemian Medical City and Baghedad Hospital, Baghdad, Iraq between January, and September 2020. The levels of indoxyl sulfate and other parameters were measured in the serum of Left ventricular hypertrophy (LVH) and compared with those with a no evidence of LVH) who considered as BMI and sex matched control group. Indoxyl sulfate (IS) levels in patients with chronic kidney disease and an evidence of lift ventricular hypertrophy (LVH-CKD) group were significantly (p=0.001) higher than those of patients with chronic kidney disease without an evidence of lift ventricular hypertrophy (NLVH-CKD) and IS levels were associated significantly with the severity of LVH. The possibility to use IS as a marker for early diagnosis of LVH in patients suffered from CKD and it can be used to determine the severity of LVH in those patients.